Seshadri Mukund, Bellnier David A, Vaughan Lurine A, Spernyak Joseph A, Mazurchuk Richard, Foster Thomas H, Henderson Barbara W
Department of Cell Stress Biology and Photodynamic Therapy Center, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Clin Cancer Res. 2008 May 1;14(9):2796-805. doi: 10.1158/1078-0432.CCR-07-4705.
The rate of energy delivery is a principal factor determining the biological consequences of photodynamic therapy (PDT). In contrast to conventional high-irradiance treatments, recent preclinical and clinical studies have focused on low-irradiance schemes. The objective of this study was to investigate the relationship between irradiance, photosensitizer dose, and PDT dose with regard to treatment outcome and tumor oxygenation in a rat tumor model.
Using the photosensitizer HPPH (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide), a wide range of PDT doses that included clinically relevant photosensitizer concentrations was evaluated. Magnetic resonance imaging and oxygen tension measurements were done along with the Evans blue exclusion assay to assess vascular response, oxygenation status, and tumor necrosis.
In contrast to high-incident laser power (150 mW), low-power regimens (7 mW) yielded effective tumor destruction. This was largely independent of PDT dose (drug-light product), with up to 30-fold differences in photosensitizer dose and 15-fold differences in drug-light product. For all drug-light products, the duration of light treatment positively influenced tumor response. Regimens using treatment times of 120 to 240 min showed marked reduction in signal intensity in T2-weighted magnetic resonance images at both low (0.1 mg/kg) and high (3 mg/kg) drug doses compared with short-duration (6-11 min) regimens. Significantly greater reductions in pO(2) were observed with extended exposures, which persisted after completion of treatment.
These results confirm the benefit of prolonged light exposure, identify vascular response as a major contributor, and suggest that duration of light treatment (time) may be an important new treatment variable.
能量传递速率是决定光动力疗法(PDT)生物学效应的主要因素。与传统的高辐照治疗不同,最近的临床前和临床研究聚焦于低辐照方案。本研究的目的是在大鼠肿瘤模型中,研究辐照度、光敏剂剂量和PDT剂量与治疗效果及肿瘤氧合之间的关系。
使用光敏剂HPPH(2-[1-己氧基乙基]-2-去乙烯基焦脱镁叶绿酸),评估了一系列包括临床相关光敏剂浓度的PDT剂量。同时进行磁共振成像和氧张力测量,并结合伊文思蓝排斥试验来评估血管反应、氧合状态和肿瘤坏死情况。
与高入射激光功率(150 mW)相比,低功率方案(7 mW)能有效破坏肿瘤。这在很大程度上与PDT剂量(药物-光产物)无关,光敏剂剂量差异高达30倍,药物-光产物差异高达15倍。对于所有药物-光产物,光治疗时间对肿瘤反应有积极影响。与短时间(6 - 11分钟)方案相比,使用120至240分钟治疗时间的方案在低剂量(0.1 mg/kg)和高剂量(3 mg/kg)药物时,T2加权磁共振图像中的信号强度均显著降低。延长照射时间后观察到pO(2)显著降低,且在治疗结束后仍持续存在。
这些结果证实了延长光照时间的益处,确定血管反应是主要因素,并表明光治疗时间(时长)可能是一个重要的新治疗变量。